Drug giant AstraZeneca has suffered a “major shareholder rebellion” over proposals to raise bonus levels for its bosses, including CEO Pascal Soriot (pictured), says Julia Bradshaw in The Daily Telegraph. While the proposals were passed, over 40% of AstraZeneca’s investors voted against them.
Soriot’s possible earnings have now climbed from 650% of his salary to 900% in just two years. The reason the revolt went as far as it did was due to opposition from Institutional Shareholder Services (ISS), which advises 4,000 clients on how they should vote, says Oliver Shah in the Sunday Times. However, while the likes of ISS can be useful in fighting “egregious bonuses”, such as those at floundering Cineworld, their “box-ticking” is unfair for Soriot, one of the few “world-class chief executives in the FTSE 100”. AstraZeneca’s share price has increased by 80% since he took over and it has developed a Covid-19 vaccine with Oxford, so“if anyone deserves a pay rise, it is Soriot”.
Soriot is a “talented chief” whose performance “actually lives up to the multimillion-pound billing” and his pay isn’t excessive compared with his contemporaries at Roche or Pfizer, says Helen Thomas in the Financial Times. Still, investors rightly worry that the dynamic in the AstraZeneca boardroom has “tipped” in favour of its “superstar boss”, who is now “being feted as the saviour of the UK’s health and economy”. The increased size and complexity that AstraZeneca is taking on with its $39bn takeover of Alexion, which shareholders also approved at the meeting, could prompt Soriot to demand even more money in future.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Unloved alternative trusts are going cheap – should you buy?Opinion Alternative trusts like infrastructure and real estate funds are trading at huge discounts. Investors should take advantage, says Rupert Hargreaves
-
Trump eyes private foundations to raise tax. Will philanthropy decline?The picture is mixed, but philanthropy on the whole is alive and well, says Simon Wilson
-
Infrastructure investing: a haven of stable growth amid market turmoilFrom booming construction in emerging markets to digital and green transitions, the infrastructure sector offers security, returns and long-term opportunities
-
The costly myth of “sell in May”Opinion May 2025's strong returns for US stocks have once again shown that putting too much weight on seasonal patterns will only make investors poorer, says Max King
-
Vietnam: a high-growth market going cheapOpinion The threat of tariffs has shaken Vietnamese stocks, but long-term prospects remain solid, says Max King
-
Who’s driving Tesla?As Elon Musk steps back from government with his eyes on the stars, investors ask if he’s still behind the wheel at his electric-car maker.
-
Cash in on the biotech boom with three promising European picksOpinion Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d put their money
-
Investment opportunities in the world of Coca-ColaThere is far more to Coca-Cola than just one giant firm. The companies that bottle and distribute the ubiquitous soft drink are promising investments in their own right.
-
Streaming services are the new magic money tree for investors – but for how long?Opinion Streaming services are in full bloom and laden with profits, but beware – winter is coming, warns Matthew Lynn
-
'Pension funds shouldn't be pushed into private equity sector'Opinion The private-equity party is over, so don't push pension funds into the sector, says Merryn Somerset Webb.
